贝伐珠单抗联合化疗治疗转移性结直肠癌的效果研究OA

Objective:To study the effect of Bevacizumab combined with chemotherapy on tumor markers and body immunity in patients with metastatic colorectal cancer(MCRC).Method:A total of 78 patients diagnosed with MCRC in Jiujiang NO.1 People's Hospital from March 2021 to December 2022 were selected and divided into groups using a random number table method,with 39 patients in each group.The control group only received FOLFOX-6 chemotherapy,and the observation group received Bevacizumab targeted therapy based on the chemotherapy conditions of the control group.The short-term efficacy,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),germ cell specific protein DDX4(DDX4)]and body immune status[CD3+,CD4+,natural killer cell(NK)]before and after treatment of the two groups were compared.Result:The objective effective rate and disease control rate of the observation group were higher than those of the control group(P<0.05).After treatment,the detection values of three tumor markers(CEA,CA19-9 and DDX4)in the observation group were lower than those in the control group(P<0.05).After treatment,the detection values of three immune indicators(CD3+,CD4+and NK)in the observation group were higher than those in the control group(P<0.05).Conclusion:Bevacizumab combined with chemotherapy can improve the short-term therapeutic effect of MCRC patients,reduce the levels of tumor markers,or it may be related to the regulation of immune status of the body.